A trial to assess the efficacy and tolerability of Hyalofill-F in non-healing venous leg ulcers

Colletta, V; Dioguardi, D; Lonardo, Antonio Di; Maggio, Giulio; Torasso, F

doi:10.12968/jowc.2003.12.9.26530

Cited by 32 publications

(13 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the banana‐leaf (122,123) and potato‐peel (124) approaches of the Third world to the sophisticated hyaluronates (125) and growth factors (126) of the developed world, much has advanced.…”

Section: Discussionmentioning

confidence: 99%

A dressing history

Queen¹,

Orsted

Sanada

et al. 2004

International Wound Journal

182

View full text Add to dashboard Cite

Over the past 30 years as caregivers, clinicians have been exposed to a plethora of new advanced wound dressings. The moist wound care revolution began in the 1970s with the introduction of film and hydrocolloid dressings, and today these are the traditional types of dressings of the advanced dressing categories. Wound-healing science has progressed significantly over the same period, as a result of intense clinical and scientific research around these product introductions. Today, the clinician understands moist wound healing, occlusion, cost effectiveness, wound bed preparation and MMP activity to name but a few of the many concepts in wound care that have flourished as a result of technology and product advancement. This review article presents a condensed history of dressing development over the past 30 years. However, in addition, such advancement is discussed in respect to its adoption in different parts of the world. The largest single markets of the world are generally the United States of America and Europe; as such, the development of both practice and technology generally begins there. Much has been written about these markets in previous review articles. For the purposes of this review, the development of wound care and the maturing of practice is discussed in respect to Canada, Japan and Australia representing smaller geographical areas where the development has been more recent but nonetheless significant.

show abstract

Section: Discussionmentioning

confidence: 99%

A dressing history

Queen¹,

Orsted

Sanada

et al. 2004

International Wound Journal

182

View full text Add to dashboard Cite

show abstract

“…Another uncontrolled, pilot trial assessed the efficacy of Hyalofill F (a partial benzyl ester derivative of HA) in the therapy of venous leg ulcers. The treatment of 20 patients showed a promising healing process and was well tolerated [56]. Again, additional clinical trials including a control group need to be performed.…”

Section: Application As Topical Agentmentioning

confidence: 98%

Hyaluronic Acid in the Treatment and Prevention of Skin Diseases: Molecular Biological, Pharmaceutical and Clinical Aspects

Weindl

Schaller²,

Schäfer‐Korting³

et al. 2004

Skin Pharmacol Physiol

165

128

View full text Add to dashboard Cite

The glycosaminoglycan hyaluronic acid (HA), or hyaluronan, is a major component of the extracellular matrix of skin, joints, eye and many other tissues and organs. In spite of its simple structure, HA demonstrates remarkable rheological, viscoelastic and hygroscopic properties which are relevant for dermal tissue function. Biological activities in skin, however, are also due to its interaction with various binding proteins (hyaladherins). Due to an influence on signaling pathways, HA is involved in the wound-healing process and scarless fetal healing. Increased HA concentrations have been associated with inflammatory skin diseases. In clinical trials, topical application of HA improved wound healing; in particular, acute radioepithelitis, venous leg ulcers or diabetic foot lesions responded to HA treatment. Moreover, as a topical drug delivery system for diclofenac, an HA gel has recently been approved for the treatment of actinic keratoses. Finally, chemical modifications led to new HA derivates and biomaterials, which may be introduced into therapy in the future. Therefore, ongoing research offers new horizons for the therapeutic use of this glycosaminoglycan which has been regarded as an inert structural component until recently.

show abstract

“…83 Silver impregnated dressings have been used to control infection and restore tissue integrity for infected ulcers, but the benefit is controversial. [84][85][86] Biologic skin substitutes derived from tissue engineering have been used in treating difficult-to-heal ulcers with some success. There seems to be an improvement in ulcer healing when added to standard compression therapy but no difference in the rate of recurrent ulcers at 1 year.…”

Section: Wound and Skin Carementioning

confidence: 99%